News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment side-effects news

Show

From To
Hepatitis C treatment
Adherence to hepatitis C treatment: unravelling the complexities

Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany

Published
13 December 2012
By
Rob Camp
Side-effects
Liver toxicity uncommon with modern antiretroviral drugs, but higher risk for HIV/HCV coinfected

Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however.

Published
06 December 2012
From
HIVandHepatitis.com
Side-effects
Copy of Liver toxicity uncommon with modern antiretroviral drugs, but higher risk for HIV/HCV coinfected

Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however.

Published
06 December 2012
From
HIVandHepatitis.com
New and experimental hepatitis C treatment
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis)

Published
05 December 2012
By
Liz Highleyman
Hepatitis C treatment side-effects
Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir

Chronic hepatitis C patients treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anaemia by either ribavirin dose reduction or addition of erythropoietin

Published
13 November 2012
By
Liz Highleyman
New and experimental hepatitis C treatment
Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C

Over 79% of previously untreated and null responder patients with genotype 1a hepatitis infection achieved a sustained virologic response twelve weeks after completing treatment (SVR12) with an interferon-free

Published
12 November 2012
By
Keith Alcorn
New and experimental hepatitis C treatment
Will Dropping Interferon Be the Magic Bullet for Reducing HCV Mortality?

Let’s start with the basic premise that most individuals with chronic hepatitis C would like to be cured of this potentially life-threatening infection. If this premise is true, why then has the large majority of HCV-infected patients in the United States not been treated with previous and current standard therapies?

Published
26 October 2012
From
Clinical Care Options (requires registration)
Hepatitis C symptoms and diagnosis
Egypt launches world’s largest Hepatitis C patient registry

In a world where data means everything for the accuracy of diagnosis, treatment and cures, Egypt took a positive step by launching a first-of-its-kind detailed patient registry.

Published
22 October 2012
From
Ahram Online
Hepatitis C treatment side-effects
European guidelines on management of mental health for people with hepatitis C published

European investigators have developed a consensus statement on hepatitis C and mental health. Published in the online edition of the Journal of Hepatology, the wide-ranging document assesses evidence

Published
16 October 2012
By
Michael Carter
Hepatitis C symptoms and diagnosis
Mental Health in Hepatitis C: A European Expert Consensus Statement

European Liver Patients Association (ELPA) invited leading psychologists, psychiatrists and hepatologists to an expert conference in 2011. Martin Schaefer MD and his colleagues reviewed the scientific data and discussed their experience in the treatment of hepatitis C related psychiatric problems. The results were first presented at the EASL conference in Berlin in 2011. Since the conference, the recommendations were refined and updated further to include the new antiviral treatments, and will now be published as a “European Expert Consensus Statement“ in the Journal of Hepatology.

Published
09 October 2012
From
European Liver Patients Association
← Prev12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.